14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CMCSA vs BMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Comcast Corp (CMCSA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CMCSA carries a Unified Composite Score of 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin), whereas BMY carries 48.9/100 (HOLD) at $58.80 (8.8x Forward P/E, 32.4% operating margin).
Technical & Structure Timing Caution: CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile BMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Telecom Services value chain with $88.3B market capitalization and 14.7% operating margin.
OpEx & R&D Reinvestment55.1% of Rev ($67.8B)
90D Engineering Disclosures0 Published
BMY Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $119.3B market capitalization and 32.4% operating margin.
OpEx & R&D Reinvestment38.1% of Rev ($19.1B)
90D Engineering Disclosures0 Published
Investor FAQ CMCSA vs BMY Key Questions & Quantitative Answers
As of Nov 20, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Comcast Corp (CMCSA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CMCSA carries a Unified Composite Score of 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin), whereas BMY carries 48.9/100 (HOLD) at $58.80 (8.8x Forward P/E, 32.4% operating margin). Technical & Structure Timing Caution: CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile BMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BMY leads the Growth & Scale pillar: CMCSA posts -6.1% YoY revenue growth and +7.8% YoY earnings growth on $123.0B TTM revenue (69.8% gross margin, 14.7% operating margin), compared with BMY at +6.9% YoY revenue growth and -2.8% YoY earnings growth on $50.0B TTM revenue (70.5% gross margin, 32.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CMCSA cumulative revenue shifted +30.9% while BMY shifted +113.6%. In operating R&D and SG&A reinvestment, CMCSA deploys 55.1% of Rev ($67.8B) (0 90-day corporate R&D disclosures) versus 38.1% of Rev ($19.1B) (0 disclosures) for BMY.
CMCSA screens cheaper on headline valuation multiples. CMCSA trades at 7.1x Forward P/E, 7.9x Trailing P/E, 1.37x PEG, and 1.4x EV/Revenue (13.9% FCF margin), whereas BMY trades at 8.8x Forward P/E, 12.9x Trailing P/E, 16.33x PEG, and 3.1x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CMCSA (11.4% ROE) versus BMY (44.0% ROE) capital efficiency.
In options market volatility and institutional positioning, CMCSA carries 36.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.01β · 32% Vol realized risk). By comparison, BMY carries 34.5% implied volatility (24th %ile, Compressed (<25th %ile)), a 1.25x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.16β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.